US-based clinical-stage biopharmaceutical company Sorrento’s subsidiary Scintilla Pharmaceuticals has completed acquiring the majority share of pharmaceutical products developer SCILEX.

Under a binding agreement announced in August last year, Scintilla acquired 72% of SCILEX's common stock for $47.6m, payable in a combination of cash and shares of Sorrento common stock.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Itochu CHEMICAL FRONTIER Corporation (ICF), a member of ITOCHU Corporation (ITOCHU), continues being the owner of the rest of 23% of SCILEX.

Sorrento paid 10% of the payment consideration at closing in common stock, while another 10% will be paid in Sorrento common stock after the resubmission of the New Drug Application (NDA) for the ZTlido product to treat postherpetic neuralgia.

"The acquisition of a majority of Scilex significantly enhances Sorrento's late-stage pipeline and footprint in the treatment of acute and chronic inflammation and pain."

Of the total $47.6m, 10% was paid by Sorrento at closing in Sorrento common stock, and 10% will be paid in Sorrento common stock upon the resubmission of the new drug application for the ZTlido product for the treatment of postherpetic neuralgia with the Food and Drug Administration (FDA).

The remaining 80% will be paid either in cash or Sorrento common stock, or in a combination of cash and Sorrento common stock upon FDA approval of the NDA.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SCILEX developed ZTlido, a branded lidocaine patch formulation to provide relief from pain of postherpetic neuralgia also referred to as after-shingles pain.

Sorrento president and CEO Dr Henry Ji said: "The acquisition of a majority of Scilex significantly enhances Sorrento's late-stage pipeline and footprint in the treatment of acute and chronic inflammation and pain.

“We are very pleased with FDA's recent guidance relating to Scilex's lead product ZTlido and believe that we have been provided a clear path to near-term resubmission.

"Through this acquisition, we have also fostered a strong relationship with Itochu Corporation, a leading Japanese company with $45bn in annual revenues.”